Belvedere Trading
DMK

Belvedere Trading’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Belvedere Trading’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-22
Closed -$260 – 1570
2022
Q4 		$260 Buy
+22
New +$251 ﹤0.01% 1106

Other funds holding DMK

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Belvedere Trading's DMK Position: Q1 2023 in Review

Belvedere Trading sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q1 2023, closing a stake of 22 shares — an estimated $260 sold.

Belvedere Trading first reported a position in DMK in Q4 2022 and held it in 1 quarter. The position peaked at $260 in Q4 2022. 47 funds tracked by Wall St. Rank hold DMK as of Q1 2023.

  • Belvedere Trading reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q1 2023 after selling out during the quarter.
  • Belvedere Trading sold 22 DMK Pharmaceuticals Corporation Common Stock shares in Q1 2023, an estimated $260.
  • Belvedere Trading first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q4 2022 and held it in 1 quarter.
  • Belvedere Trading's DMK Pharmaceuticals Corporation Common Stock position peaked at $260 in Q4 2022.
  • 47 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q1 2023.

Based on Belvedere Trading's 13F filing for Q1 2023, filed 15 May 2023.